par Heath, Elisabeth I;Lorusso, Patricia;Ramalingam, Suresh S;Awada, Ahmad ;Egorin, Merrill J;Besse-Hammer, Tatiana;Cardoso, Fatima ;Valdivieso, Manuel;Has, Teresa;Alland, Leila;Zhou, Xiaofei;Belani, Chandra P
Référence Investigational new drugs, 29, 6, page (1426-1431)
Publication Publié, 2011-12
Référence Investigational new drugs, 29, 6, page (1426-1431)
Publication Publié, 2011-12
Article révisé par les pairs
Titre: |
|
Auteur: | Heath, Elisabeth I; Lorusso, Patricia; Ramalingam, Suresh S; Awada, Ahmad; Egorin, Merrill J; Besse-Hammer, Tatiana; Cardoso, Fatima; Valdivieso, Manuel; Has, Teresa; Alland, Leila; Zhou, Xiaofei; Belani, Chandra P |
Informations sur la publication: | Investigational new drugs, 29, 6, page (1426-1431) |
Statut de publication: | Publié, 2011-12 |
Sujet CREF: | Cancérologie |
Mots-clés: | Oral |
Paclitaxel | |
Phase I | |
MeSH keywords: | Administration, Oral |
Aged | |
Antineoplastic Agents -- administration & dosage -- adverse effects -- pharmacokinetics | |
Bridged Compounds -- administration & dosage -- adverse effects -- pharmacokinetics | |
Dose-Response Relationship, Drug | |
Drug Administration Schedule | |
Female | |
Humans | |
Male | |
Middle Aged | |
Neoplasms -- drug therapy -- pathology | |
Neutropenia -- chemically induced | |
Sepsis -- chemically induced | |
Treatment Outcome | |
Note générale: | Clinical Trial, Phase I |
Journal Article | |
Multicenter Study | |
SCOPUS: ar.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:0167-6997 |
info:doi/10.1007/s10637-010-9498-z | |
info:scp/84856051059 | |
info:pmid/20680660 |